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Context: Posttransplantation diabetes mellitus (PTDM) is a major metabolic complication in renal
transplant recipients. Adiponectin (ADIPOQ) and adiponectin receptor-1 (ADIPOR1) gene poly-
morphisms have been associated with type 2 diabetes. However, it is unknown whether these
polymorphisms are also risk factors for PTDM.
Objective:We investigated the association between PTDM and single-nucleotide polymorphisms
of ADIPOQ and ADIPOR1 in a cohort of renal allograft recipients.
Design, Setting, and Participants: Five hundred seventy-five patients (367 men and 208 women) who
receivedkidneytransplantsbetween1989and2007,withoutahistoryofdiabetesandwithapretransplant
fasting glucose concentration less than 5.5mmol/liter. Patients were followed up for amedian 10 yr. Ge-
notypesincludedsingle-nucleotidepolymorphismsofthefollowing:ADIPOQrs266729,rs822395,rs822396,
rs2241766, and rs1501299 andADIPOR1 rs2232853, rs12733285, and rs1342387.
Results: TT-homozygotes in ADIPOQ rs1501299 [hazard ratio (HR)  1.70, P  0.032] had greater
risk of PTDMafter adjusting for age, sex, amount ofweight gain, and type of immunosuppressant.
There was a significant interaction between sex and ADIPOQ rs1501299 genotype (P  0.037). In
men, but not inwomen, TT-homozygotes inADIPOQ rs1501299weremore likely to develop PTDM
than the wild GG-homozygotes (HR  2.50, P  0.002), whereas GT-heterozygotes had nonsig-
nificantly elevated risk (HR  1.41, P  0.128).
Conclusion: Genetic variation in ADIPOQ rs1501299 is associated with PTDM in a sex-specific
manner. (J Clin Endocrinol Metab 97: E129–E135, 2012)
Use of immunosuppressive medications hasminimizedthe incidence of rejection of transplanted organs
and increased patient survival. With increased transplant
recipient life expectancy, however, many chronic compli-
cations of organ transplantation have emerged, the most
important of which is cardiovascular disease (1). Several
studies have shown that metabolic abnormalities includ-
ing diabetes and dyslipidemia are important contributors
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to cardiovascular mortality in transplant recipients (2).
Posttransplantation diabetes mellitus (PTDM), or new-
onset diabetes after transplantation, is a common serious
complication after organ transplantation and is associated
with increased morbidity, cardiovascular mortality, and
graft loss (1–3). The reported incidence of PTDM varies
but increases with time after transplantation (3). Renal
allograft recipients are at high risk for developing diabetes
mellitus due to a number of factors including aging, obe-
sity, and corticosteroid and immunosuppressive medica-
tion use. In addition, we have previously reported that
genetic factors have an important role in the development
of PTDM (4–6).
Adiponectin gene (ADIPOQ; gene identification9370,
GenBank identification NM_004797) polymorphisms
have been shown to be associated with type 2 diabetes,
although some controversies remain (7). Also, the poly-
morphisms in the adiponectin receptor-1 gene (ADIPOR1;
gene identification 51094, GenBank identification NM_
015999) have been associated with insulin resistance and
diabetes mellitus (8, 9). Adiponectin concentrations in
plasma and the expression of adiponectin receptor-1 are
lower in patients with diabetes than in healthy subjects
(10). The association of these polymorphismswith PTDM
has never been examined. In this study, we evaluated sin-
gle-nucleotide polymorphisms (SNP) in genes encoding
adiponectin and its type 1 receptor in a large cohort of




Unrelated renal transplant recipients were recruited from the
Severance Hospital Transplantation Center, Yonsei University
Health System. PTDMwas diagnosed 1 yr after transplantation
as previously described (4–6), according to the International
Consensus Guidelines for the diagnosis and management of
PTDM (11–13). Patients who started antidiabetic medication
(oral medication or insulin) after transplantation and continued
themedication thereafterwere included in thePTDMgroup.The
rest of the patients were assigned to the non-PTDM group. Ac-
cording to our previous study (14), cases of persistent PTDM
(patients who developed diabetes within 1 yr after transplanta-
tion and remained diabetic) and late PTDM (patients who de-
veloped diabetes after 1 yr after transplantation) were assigned
to the PTDM group. Transient PTDM cases (patients who de-
veloped diabetes within 1 yr after transplantation but eventually
recovered tonormoglycemiawithoutmedication)were classified
as non-PTDM. Patients were eligible to participate in the study
if they were recipients of a kidney allograft with no other history
of organ transplantation and were followed up for at least 1 yr.
Only individuals with no previous diagnosis of diabetes and pre-
transplant fasting plasma glucose (FPG) concentration less than
5.5 mmol/liter were included. Patients were excluded if they had
a history of diabetes before transplantation, severe metabolic or
infectious disease, or FPG concentration 5.5 mmol/liter or
greater.
A total of 805 unrelated transplant recipients were recruited
from 1989 to 2007. Of 805 patients screened, 103 patients were
excluded because they had a recorded FPG concentration 5.5
mmol/liter or greater. Thirty patients had diabetes before trans-
plantation, 35 patients had repeated renal allograft operation,
and 13 patients were younger than 18 yr. Among the remaining
624 patients,DNA sampleswere available for 575 (367men and
208 women). Medical histories were obtained, anthropometric
measurements were taken, and blood samples were collected
after an overnight fast at the time of transplantation and again at
3, 6, and 12 months after transplantation. FPG concentration
was determined by using an enzymatic colorimetric assay. The
internal review board of Severance Hospital approved the study
protocol, and all subjects were provided with adequate infor-
mation about this study and gave informed consent.
Immunosuppressant medications
Themain immunosuppressive regimens consistedof calcineu-
rin inhibitors and glucocorticoids. Detailedmedication schedule
is describedpreviously (4, 6).Calcineurin inhibitors (cyclosporin
or tacrolimus) were the main immunosuppressant medications
used. Prednisolone anddeflazacortwere themain glucocorticoid
regimens used in the prevention of rejection. The usual dose of
prednisolone was 10 mg/d and that of deflazacort was 12 mg/d.
Because prednisolone is known to be 1.2–1.5 times more potent
than deflazacort, we converted the deflazacort dose to a corre-
sponding prednisolone dose by multiplying by 0.8.
Gene and SNP selection
The ADIPOQ maps to 3q27 and has more than 10 tagging
SNP (15, 16) and two haplotype blocks between 2049 and
450 (17, 18).We chose four intronic SNP and one exonic SNP
togenotype these twoblocks.Wechose togenotype rs266729 (5
flanking region), rs822395 (intron 1), and rs822396 (intron 1)
to tag block 1 and rs1501299 (intron 2) and rs2241766 (exon 2)
to tag block 2 because these SNP are the five most common SNP
and have been studied extensively by others as to their function-
ality and in relation to diabetes (7, 15, 19, 20). Also, we selected
only SNP with a minimum allele frequency of 10% in Koreans.
ADIPOR1 has more than 28 SNP in two linkage disequilib-
rium blocks (17, 21). One block extends from the 5 flanking
region to intron4 and the other is located at the 3 endof the gene
(17). Based on this structure, we selected five common SNP for
genotyping. For block 1, we selected the following tagging SNP:
rs2232853 (5 flanking region), rs12733285 (intron 1), and
rs1342387 (intron 4). For block 2, we selected rs7539542 (exon
8) and rs10920531 (3 flanking region). However, minimum
allele frequency of the two SNP in block 2 was less than 10%, so
we excluded these two SNP (rs7539542 and rs10920531) from
further analysis.
Genotyping and quality control
Genomic DNA was isolated from peripheral blood lympho-
cytes using the QIAamp DNA blood minikit (Qiagen, Valencia,
CA). Genotyping was performed using a TaqMan SNP geno-
typing assay system (Applied Biosystems, Foster City, CA).
Genotyping for all eight SNP was performed by Taq man SNP
allelic discrimination bymeans of an ABI 7900HT (Applied Bio-
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systems). The assay mix identifications were C2412786_10 for
ADIPOQ rs266729, C2910317_10 for ADIPOQ rs822395,
C2910316_10 for ADIPOQ rs822396, C26426077_10 for
ADIPOQ rs2241766, C7497299_10 forADIPOQ rs1501299,
C198957_10 for ADIPOR1 rs2232853, C26186730_10 for
ADIPOR1 rs12733285, and C37350_10 for ADIPOR1
rs1342387. A total of 58 samples (10%) were genotyped in du-
plicate and showed 100% concordance. A total of 48 duplicate
samples and negative controls (7.6%) were included to ensure
the accuracy of the genotyping, and 100% of the duplicates rep-
licated the original genotype.
Statistical analyses
We analyzed the 10 SNP in each of the 575 renal transplant
patients. For all SNP, compliance with the Hardy-Weinberg
equilibrium was assessed using the 2 test. The genotype fre-
quencies were compared between the non-PTDM and PTDM
groups using Pearson’s 2 test in additive, codominant 1 (major
allele homozygotes vs. heterozygotes), codominant 2 (major al-
lele homozygotes vs.minor allele homozygotes), dominant (ma-
jor allele homozygotes vs. minor allele homozygotes plus
heterozygotes), and recessive (major allele homozygotes plus
heterozygotes vs. minor allele homozygotes) models. The allele
frequencies were also compared using Pearson’s 2 test. All con-
tinuous variables are expressed as themean SD. Student’s t test
was used to compare continuous variables and the 2 test was
used to compare categorical variables between the PTDM and
non-PTDMgroups. ACox proportional hazardmodel was used
to identify risk factors for PTDMdevelopment and calculate the
adjusted hazard ratio (HR) and 95% confidence intervals, after
controlling for potential risk factors (age, sex, amount of weight
gain, and type of main immunosuppressant used).
Interactions between genotype and sex were assessed using
multivariate Cox models. To avoid any false-positive result due
to multiple comparisons, conservative Bonferroni correction
was applied. A P  0.00313 [0.05 divided by 16, i.e. the total
number of SNP studied in this study plus the number of SNP that
showed significant results in previous studies (4–6)] was con-
sidered significant.
SPSS version 12.0 (SPSS Inc., Chicago, IL), StatMate version
2.00 (GraphPad, La Jolla, CA), and Prism version 5.04 (GraphPad)
were used in the statistical analysis and graph construction.
Results
Clinical characteristics of patients
PTDM patients were significantly older than non-
PTDM patients at the time of transplantation (Table 1).
The mean follow-up time was 156 months (13 yr) for the
PTDM group and 143 months (12 yr) for the non-PTDM
group (P  0.027). The initial body weight was not sig-
nificantly different between the two groups, but PTDM
patients gained more body weight than non-PTDM pa-
tients at 6 months after transplantation (Table 1). PTDM
patients had greater FPG concentration than non-PTDM
patients at 3 months after transplantation onward, de-
spite the use of antidiabetic treatment (Table 1). There
was no significant difference in the mean daily steroid
dose between the PTDM group and the non-PTDM
group (Table 1).
Genotype distribution and association between
genotype and PTDM
All SNPdidnotdeviate fromtheHardy-Weinberg equi-
librium.Noneof eight SNPwasnominally associatedwith
PTDM development in additive, codominant 1, codomi-
nant 2, dominant, or recessive models (Table 2). In addi-
TABLE 1. Clinical characteristics of the study population
PTDM Non-PTDM P value
n (female) 154 (58) 421 (150) 0.653a
Age (yr) at transplantation 42.3  9.2 37.3  9.4 3.04  108
Age at transplantation older than 40 yr 92 (59.7%) 161 (38.2%) 4.25  106
Family history of diabetes (%) 47 (32.4%) 149 (33.6%) 0.398a
Follow-up duration (months) 155.8  62.0 143.0  61.4 0.027
BW (kg) at transplantation 59.8  9.6 58.8  9.9 0.269
BW (kg) at 6 months after transplantation 63.0  8.8 61.0  9.1 0.018
 BW during first 6 months after transplantation 3.3  5.7 2.2  5.4 0.049
Baseline body mass index 21.87  3.37 21.42  2.91 0.155
FPG (mg/dl) at transplantation 91.6  12.5 93.8  13.9 0.093
FPG (mg/dl) at 3 months after transplantation 117.9  43.3b 96.5  13.9b 1.11  108
FPG (mg/dl) at 6 months after transplantation 120.7  50.7b 96.7  13.9b 3.28  108
FPG (mg/dl) at 12 months after transplantation 127.4  46.8b 97.0  14.6b 7.07  1013
Fasting plasma insulin (pmol/liter) 48.23  26.15 48.44  29.05 0.945
Patients with tacrolimus use, n 48 (31.2%) 83 (19.7%) 0.005a
Mean daily steroid dose (mg/d) 9.76  1.17 9.57  1.41 0.107
Serum creatinine (mg/dl) 6 months after transplantation 1.31  0.43 1.32  0.34 0.602
Serum creatinine (mg/dl) 12 months after transplantation 1.33  0.64 1.30  0.35 0.378
Data are presented as the mean  SD or n (%) unless otherwise indicated. P values were calculated from t tests. Mean daily steroid dose is shown
in prednisolone equivalent dose. BW, Body weight;  BW, change in body weight.
a P values were calculated from 2 tests.
b Includes patients with antidiabetic medications.
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tion, no significant nominal associationbetweenallele and
PTDMwas observed (Table 2). Haplotype information is
shown in Supplemental Tables A1 and A2 and Supple-
mental Figs. A1 and A2, published on The Endocrine So-
ciety’s JournalsOnlinewebsiteathttp://jcem.endojournals.
org. We used Cox proportional hazard regression test to
analyze the genetic effect on PTDM development, includ-
ing age, sex, amount of postoperative weight gain, type of
immunosuppressant, and genotype as covariates in the
regression model. As shown in Table 3, TT-homozygotes
inADIPOQ rs1501299 (HR1.70,P0.032) had greater
risk of PTDM after adjusting for age, sex, amount of
weight gain, and type of immunosuppressant.
Multivariate logistic regression analysis for risk
factors associated with PTDM
Age at transplantation was the strongest risk factor for
development of PTDM (Table 4). Tacrolimus use as the
main immunosuppressant was 2.5 times more likely to
lead to the development of PTDM than cyclosporin use
(Table 4). Preoperative baseline fasting plasma glucose
was not associated with PTDM development. ADIPOQ
rs1501299 TT genotype was significantly associated with
PTDM(P0.038),whereas theTGgenotypedidnot (P
0.149). There was an interaction between ADIPOQ
rs1501299 genotype and sex, which significantly affected
the effect of this polymorphism on the development of
PTDM (P  0.037) (Table 4). After Bonferroni adjust-
ment for multiple comparisons (P  0.05, 16 SNP), men
with the TT genotype at ADIPOQ rs1501299 had a sig-
nificantly greater risk of PTDMthan theGGhomozygotes
(HR2.50,P 0.002, Fig. 1, top panel). GT heterozygotes
had nonsignificantly elevated risk (HR 1.41, P  0.128,
Fig. 1, top panel). However, among women, no such ge-
netic effect was observed (TT: HR 0.70, P  0.430 and
GT: HR 1.14, P 0.637) (Fig. 1, bottom panel). No sig-
nificant interaction between ADIPOQ rs1501299 geno-
type and type of immunosuppressant was observed (P 
0.755).
Discussion
In this study, we analyzed the relationships of ADIPOQ
and ADIPOR1 polymorphisms with PTDM.We found a
sex-specific association of theADIPOQ rs1501299 poly-
morphism with the development of PTDM in renal allo-
graft recipients, with the TT genotype conferring signifi-
cantly greater risk of PTDM in men but not in women.
Likewise, Yamaguchi et al. (22)reported that the T al-
lele in theADIPOQ rs1501299 represents a risk factor for
type 2 diabetes only in men, and Sun et al. (23) made
similar observations for the PPARGC1 gene in Chinese
subjects. Becausemost of the female patients participating
in our study were relatively young and thus still reproduc-
tively active (i.e. not likely to be postmenopausal), our













rs266729 CC 96 62.34 225 53.44 0.087 0.057 0.597 0.057 0.597 0.901
CG 47 30.52 171 40.62
GG 11 7.14 25 5.94
rs822395 AA 128 83.12 342 81.24 0.861 0.653 0.738 0.605 0.350 0.118
AC 24 15.58 72 17.10
CC 2 1.30 7 1.66
rs822396 AA 133 86.36 350 83.14 0.509 0.478 0.344 0.350 0.055
AG 20 12.99 64 15.20
GG 1 0.65 7 1.78
rs2241766 TT 67 43.51 216 51.31 0.248 0.100 0.461 0.098 0.751 0.756
TG 73 47.40 170 40.38
GG 14 9.09 35 8.31
rs1501299 GG 70 45.45 216 51.31 0.176 0.484 0.063 0.214 0.083 0.127
GT 62 40.26 166 39.43
TT 22 14.29 39 8.48
rs2232853 CC 149 96.75 398 94.54 0.274 0.274 0.274 0.550
CT 5 3.25 23 5.46
TT 0 0.00 0 0.00
rs12733285 CC 139 90.26 361 85.75 0.227 0.120 0.485 0.155 0.700
CT 14 9.09 59 14.01
TT 1 0.65 1 0.24
rs1342387 GG 27 17.53 79 18.76 0.800 0.565 0.972 0.667 0.736 0.784
AG 78 50.65 200 47.51
AA 49 31.82 142 33.73
P values were calculated from Pearson’s 2 test. HWE, Hardy-Weinberg equilibrium; codominant 1, major allele homozygotes vs. heterozygotes,
codominant 2, major allele homozygotes vs. minor allele homozygotes; dominant, major allele homozygotes vs. minor allele homozygotes plus
heterozygotes; recessive, major allele homozygotes plus heterozygotes vs. minor allele homozygotes.
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results may reflect an interaction between estrogen avail-
ability and adiponectin. Although clinical studies on the
association between estrogen replacement therapy and se-
rumadiponectin levels are conflicting (24–26), estrogen is
believed to have antidiabetic effects in skeletal muscle
cells, adipocytes, and pancreatic islets (27), and estrogen
receptor gene polymorphisms have been associated with
circulating adiponectin concentrations (28). Whether
there is cross talk between estrogen availability and adi-
ponectin action requires further investigation.
A previous study has shown that the ADIPOQ
rs1501299 (G276T) polymorphism is associated with
type 2 diabetes mellitus, with the G allele conferring
greater risk for diabetes, more insulin resistance, and
lower plasma adiponectin concentration (15). However,
similar to our results, another study performed in a large
cohort reported that the T allele of ADIPOQ rs1501299
represents a risk factor for diabetes (22, 29). Although
according to ametaanalysis, polymorphisms ofADIPOQ
rs1501299 gene are not significantly associated with di-
abetes, with relative risks for the GT and TT genotypes
being 0.98 and 0.95, respectively, when compared with
the GG genotype (7). The reasons for these discrepant
results between studies are not clear but could be related
to different subject characteristics and/or possible differ-
ential genetic effects, depending on ethnicity. Herein we
studied renal allograft recipients for the first time,whereas
TABLE 3. Cox proportional hazard regression analysis
of genotypes associated with PTDM
Genotype Adjusted HR (95% CI) P valuea
rs266729 CC 1.00
CG 0.64 (0.44–0.92) 0.015
GG 1.08 (0.58–2.03) 0.804
rs822395 AA 1.00
AC 0.90 (0.58–1.41) 0.647
CC 0.86 (0.21–3.51) 0.833
rs822396 AA 1.00
AG 0.84 (0.52–1.36) 0.488
GG 0.62 (0.09–4.48) 0.636
rs2241766 TT 1.00
TG 1.34 (0.95–1.34) 0.095
GG 1.27 (0.71–2.28) 0.423
rs1501299 GG 1.00
GT 1.21 (0.85–1.73) 0.283
TT 1.70 (1.05–2.76) 0.032
rs2232853 CC 1.00
CT 0.42 (0.28–0.69) 0.423
rs12733285 CC 1.00
CT 0.77 (0.44–1.33) 0.344
TT 0.99 (0.13–7.44) 0.994
rs1342387 GG 1.00
AG 1.09 (0.75–1.57) 0.665
AA 1.03 (0.63–1.68) 0.917
a P values for each SNP were adjusted for age, sex, amount of body
weight gain, and type of immunosuppressant regimen (0, cyclosporine
A; 1, tacrolimus). CI, Confidence interval.
TABLE 4. Multivariate logistic regression analysis for
risk factors associated with PTDM
HR (95% CI) P value
Age (yr) 1.06 (1.04–1.08) 0.001
Sex (0, male; 1, female) 0.98 (0.70–1.37) 0.905
FPG at baseline 1.01 (0.99–1.02) 0.254
Weight gain 1.02 (0.99–1.05) 0.295
Type of immunosuppressant (0,
cyclosporin A; 1, tacrolimus)
2.42 (1.63–3.57) 0.001
Genotype (0, wild homozygote;
1, heterozygote)
1.29 (0.91–1.82) 0.149




FIG. 1. Cox proportional hazard regression analysis of PTDM
development and ADIPOQ rs1501299 according to sex. Men with the
TT genotype at ADIPOQ rs1501299 had a significantly greater risk of
PTDM development than the GG homozygotes (HR 2.50, P  0.002,
top panel). GT heterozygotes had nonsignificantly elevated risk of
PTDM (HR 1.41, P  0.128, top panel). However, among women, no
such genetic effect was observed (TT: HR 0.70, P  0.430 and GT: HR
1.14, P  0.637, bottom panel).
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previous studies examined patients with diabetes not oc-
curring in the context of renal transplantation. A number
of studies on ADIPOQ rs1501299 reported that the T
allele is associated with increased adiponectin concentra-
tion in plasma (20, 30). ADIPOQ rs1501299 is located
in intron 2, and it is possible that this polymorphism is in
linkage with other polymorphisms that are involved in
insulin secretion or insulin resistance. Also, we cannot
exclude the possibility that someof these associationsmay
have occurred by chance. Exact mechanisms underlying
ourobservationsneed tobe explored indetail in the future.
Although steroid use is known to be diabetogenic, we
found no association between PTDM and steroid dose.
This is probably due to low dose of steroids used in our
study patients and/or the overwhelming effects of other
factors.
Our study has several limitations. Oral glucose toler-
ance tests were not routinely performed before transplan-
tation, and preexisting diabetes or impaired glucose tol-
erance could have led to an overestimation of PTDM
incidence. As we reported previously, there could be a
phenotype change from PTDM to non-PTDMmainly due
to steroid pulse therapy to treat acute rejection. To min-
imize the effect of phenotype change and avoid this pos-
sible confounding, we included only renal allograft pa-
tients who were followed up more than 1 yr and
determined the PTDM phenotype at 1 yr after transplan-
tation. Another limitation is the lack of measurements of
plasma adiponectin concentration before transplantation
due to lack of samples. However, it has been shown that
patients with end stage renal disease have elevated plasma
adiponectin concentration and plasma adiponectin does
not correlate with insulin sensitivity (31, 32). Finally, the
relatively small sample size precluded the study of gene-
gene interactions. However, our study included a unique
cohort of diabetic patients and over a relatively long-term
observational period (median of 10 yr). Although itwould
be desirable to have confirmed our results in another
smaller cohort of transplant patients, this was not feasible
in this study. Larger studies are therefore required to con-
firm our results in different populations and ethnicities
and evaluate the prognostic significance of our findings.
In conclusion, our results suggest that genetic variation
in ADIPOQ is associated with PTDM. Variants of the
ADIPOQ rs1501299 are linked to PTDM development
only in male but not in female renal allograft recipients.
This indicates a possible sex-specific effect of adiponectin
on the development of PTDM in this population.
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